, Tracking Stock Market Picks
Enter Symbol:

up 126.36 %

COVIDIEN LTD. COMMON SHARES (COV) rated Outperform with price target $60 by Leerink Swann

Posted on: Monday,  Jun 23, 2008  8:25 AM ET by Leerink Swann

Leerink Swann rated Outperform COVIDIEN LTD. COMMON SHARES (NYSE: COV) on 06/23/2008, when the stock price was $47.14.
Since then, COVIDIEN LTD. COMMON SHARES has gained 126.37% as of 01/26/2016's recent price of $106.71.
If you would have followed this Leerink Swann 's recommendation on COV, you would have gained 126.36% of your investment in 2773 days.

Covidien is a leading global healthcare products company that creates innovative medical solutions for better patient outcomes and delivers value through clinical leadership and excellence. Covidien manufactures, distributes and services a diverse range of industry-leading product lines, including Surgical Devices, Energy-Based Devices, Respiratory and Monitoring Solutions, Patient Care and Safety Products, Imaging Solutions, Pharmaceutical Products, Medical Supplies and Retail Products.

Leerink Swann Equity Research provides unique perspectives and agenda-setting healthcare recommendations for investors. Supported by industry-based intelligence and thorough market examination, our proprietary research enables our clients to make well-informed healthcare investment decisions. Our investment perspectives are driven by proprietary insights from MEDACorp. MEDACorp's more than 25,000 network professionals work with new and/or development-stage pharmaceuticals, medical devices and biotherapeutics on a daily basis. MEDACorp's extensive knowledge of products and research enables Leerink Swann to provide growth-focused clients an expertise earned through experience.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
6/23/2008 8:25 AM Buy
47.14 60.00
as of 12/24/2008
1 Week down  -5.07 %
1 Month up  3.18 %
3 Months down  -5.37 %
1 YTD down  -29.80 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy